3 min read · 08 February 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has agreed to acquire LEAD Therapeutics Inc., a San Bruno, Calif.-based drug company whose lead product is for patients with rare, genetically-defined cancers. The deal could be worth upwards of $97 million, including an $18 million up-front payment. LEAD has raised around $22 million in VC funding from ProQuest Investments, Pappas Ventures and Mustang Ventures.
4 min read · 05 February 2010
Gigamon, a Milpitas, Calif.-based provider of data access networking solutions, has raised $22.8 million from Highland Capital Partners. It is the company's first round of institutional funding.
3 min read · 05 February 2010
Layered Technologies Inc., a Plano, Texas-based provider of on-demand and cloud computing IT infrastructure, has raised $20 million in growth equity funding. Accel-KKR led the round, and was joined by return backers Enhanced Equity Fund and Pangloss International.
3 min read · 05 February 2010
Quantiam Technologies, an Edmonton, Alberta-based advanced materials company, has raised $6 million from BASF Venture Capital and Ursataur Capital Management.
3 min read · 05 February 2010
3 min read · 05 February 2010
Allergan Inc. (NYSE: AGN) has acquired Serica Technologies Inc., a Medford, Mass.-based developer of a silk-based biomaterial platform for connective tissue repair. No financial terms were disclosed. Serica had raised around $14.5 million in VC funding, from Prism VentureWorks, Morningside Technology Ventures and Ivy Capital Partners.
4 min read · 05 February 2010
2 min read · 04 February 2010
LensVector Inc., a maker of optical components for consumer electronics, today announced it has closed $30 million in a Series C financing round, bringing the total financial backing of the company to more than $50 million. Institutional Venture Partners (IVP) led the new funding and joins existing investors Menlo Ventures, Samsung, Silicon Valley Bank, Mitsui and Kodak.
3 min read · 04 February 2010
Sistemic Ltd, a Scottish biotech company, closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company develops its drug discovery technology.
2 min read · 04 February 2010
